What is the standard of care for metastatic Liver Cancer according to NCCN guidelines

Standard of Care for Metastatic Liver Cancer (HCC)

Based on the NCCN Guidelines Version 2.2025 for Hepatocellular Carcinoma, here's what the standard of care looks like for metastatic (spread) liver cancer:

Initial Assessment & Workup

Before treatment decisions are made, your care team should perform:

• Imaging studies: Multiphasic (multiple phase) contrast-enhanced CT or MRI of the abdomen, chest CT, and pelvis imaging to identify where the cancer has spread
• Hepatitis testing: Blood tests for hepatitis B and C, since these are common causes of liver cancer
• Liver function evaluation: Tests to assess how well your liver is working and whether portal hypertension (high blood pressure in liver vessels) is present
• Biopsy consideration: According to NCCN Guidelines, a biopsy should be considered for patients with advanced disease to confirm the diagnosis, since imaging criteria are less reliable in advanced stages

Treatment Approach for Metastatic Disease

According to the NCCN Guidelines, patients with extrahepatic/metastatic disease (cancer that has spread outside the liver) who are not candidates for surgery, transplant, or locoregional therapy (local treatments like ablation or radiation) typically receive:

First-Line Systemic Therapy (medication-based treatment)

The guidelines recommend systemic therapy as the primary treatment approach, which may include:

• Immunotherapy combinations (checkpoint inhibitors)
• Targeted therapy based on molecular profiling (genetic testing of the tumor)
• Clinical trials (often listed as preferred option)

Response Assessment

Your oncologist will monitor your response through:

• Imaging every 3-6 months initially
• Assessment of whether the cancer is responding, stable, or progressing

If Disease Progresses

The NCCN Guidelines outline options for subsequent treatment:

• Subsequent-line systemic therapy (different medication regimens)
• Reconsideration of locoregional therapy with multidisciplinary review
• Clinical trials
• Best supportive care (palliative care focused on comfort and quality of life)

Key Clinical Considerations

According to NCCN Guidelines, treatment decisions depend on:

• Extent of disease (how much cancer is present)
• Hepatic reserve (how much healthy liver function remains)
• Performance status (your overall health and ability to tolerate treatment)
• Institutional capabilities (what treatments your center offers)

Important Note About Molecular Profiling

The NCCN Guidelines emphasize that tumor molecular profiling should be considered in all patients with advanced stages of disease to identify potential targeted aberrations (specific genetic mutations) that may respond to targeted therapies.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.